Literature DB >> 18353963

Structural and nonstructural protein genome regions of eastern equine encephalitis virus are determinants of interferon sensitivity and murine virulence.

Patricia V Aguilar1, A Paige Adams, Eryu Wang, Wenli Kang, Anne-Sophie Carrara, Michael Anishchenko, Ilya Frolov, Scott C Weaver.   

Abstract

Eastern equine encephalitis virus (EEEV) causes sporadic epidemics of human and equine disease in North America, but South American strains have seldom been associated with human neurologic disease or mortality, despite serological evidence of infection. In mice, most North American and South American strains of EEEV produce neurologic disease that resembles that associated with human and equine infections. We identified a South American strain that is unable to replicate efficiently in the brain or cause fatal disease in mice yet produces 10-fold higher viremia than virulent EEEV strains. The avirulent South American strain was also sensitive to human interferon (IFN)-alpha, -beta, and -gamma, like most South American strains, in contrast to North American strains that were highly resistant. To identify genes associated with IFN sensitivity and virulence, infectious cDNA clones of a virulent North American strain and the avirulent South American strain were constructed. Two reciprocal chimeric viruses containing swapped structural and nonstructural protein gene regions of the North American and South American strains were also constructed and found to replicate efficiently in vitro. Both chimeras produced fatal disease in mice, similar to that caused by the virulent North American strain. Both chimeric viruses also exhibited intermediate sensitivity to human IFN-alpha, -beta, and -gamma compared to that of the North American and South American strains. Virulence 50% lethal dose assays and serial sacrifice experiments further demonstrated that both structural and nonstructural proteins are important contributors to neurovirulence and viral tissue tropism. Together, the results of this study emphasize the complex and important influences of structural and nonstructural protein gene regions on EEEV virulence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18353963      PMCID: PMC2346730          DOI: 10.1128/JVI.02514-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Large-plaque mutants of Sindbis virus show reduced binding to heparan sulfate, heightened viremia, and slower clearance from the circulation.

Authors:  A P Byrnes; D E Griffin
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  [Eastern equine encephalitis].

Authors:  R F FEEMSTER; W HAYMAKER
Journal:  Neurology       Date:  1958-11       Impact factor: 9.910

3.  Mechanism of altered Sindbis virus neurovirulence associated with a single-amino-acid change in the E2 Glycoprotein.

Authors:  P C Tucker; D E Griffin
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

4.  A single amino acid change in the E2 glycoprotein of Sindbis virus confers neurovirulence by altering an early step of virus replication.

Authors:  L K Dropulic; J M Hardwick; D E Griffin
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

5.  Sindbis virus mutations which coordinately affect glycoprotein processing, penetration, and virulence in mice.

Authors:  D L Russell; J M Dalrymple; R E Johnston
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

6.  Proposed antigenic classification of registered arboviruses I. Togaviridae, Alphavirus.

Authors:  C H Calisher; R E Shope; W Brandt; J Casals; N Karabatsos; F A Murphy; R B Tesh; M E Wiebe
Journal:  Intervirology       Date:  1980       Impact factor: 1.763

7.  The use of chimeric Venezuelan equine encephalitis viruses as an approach for the molecular identification of natural virulence determinants.

Authors:  A M Powers; A C Brault; R M Kinney; S C Weaver
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

8.  Expression of the zinc-finger antiviral protein inhibits alphavirus replication.

Authors:  Matthew J Bick; John-William N Carroll; Guangxia Gao; Stephen P Goff; Charles M Rice; Margaret R MacDonald
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 9.  Genetic determinants of Venezuelan equine encephalitis emergence.

Authors:  S C Weaver; M Anishchenko; R Bowen; A C Brault; J G Estrada-Franco; Z Fernandez; I Greene; D Ortiz; S Paessler; A M Powers
Journal:  Arch Virol Suppl       Date:  2004

10.  Molecularly engineered resistance to California serogroup virus replication in mosquito cells and mosquitoes.

Authors:  A M Powers; K I Kamrud; K E Olson; S Higgs; J O Carlson; B J Beaty
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

View more
  38 in total

Review 1.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.

Authors:  Farooq Nasar; Demetrius Matassov; Robert L Seymour; Theresa Latham; Rodion V Gorchakov; Rebecca M Nowak; Grace Leal; Stefan Hamm; John H Eldridge; Robert B Tesh; David K Clarke; Scott C Weaver
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

3.  Evolutionary patterns of eastern equine encephalitis virus in North versus South America suggest ecological differences and taxonomic revision.

Authors:  Nicole C Arrigo; A Paige Adams; Scott C Weaver
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

4.  Chimeric alphavirus vaccine candidates protect mice from intranasal challenge with western equine encephalitis virus.

Authors:  Svetlana Atasheva; Eryu Wang; A Paige Adams; Kenneth S Plante; Sai Ni; Katherine Taylor; Mary E Miller; Ilya Frolov; Scott C Weaver
Journal:  Vaccine       Date:  2009-05-27       Impact factor: 3.641

5.  Susceptibility of the Aotus nancymaae owl monkey to eastern equine encephalitis.

Authors:  Benjamin J Espinosa; Scott C Weaver; Slobodan Paessler; Douglas Brining; Milagros Salazar; Tadeusz Kochel
Journal:  Vaccine       Date:  2009-01-30       Impact factor: 3.641

6.  Chimeric alphavirus vaccine candidates for chikungunya.

Authors:  Eryu Wang; Eugenia Volkova; A Paige Adams; Naomi Forrester; Shu-Yuan Xiao; Ilya Frolov; Scott C Weaver
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

7.  Eastern and Venezuelan equine encephalitis viruses differ in their ability to infect dendritic cells and macrophages: impact of altered cell tropism on pathogenesis.

Authors:  Christina L Gardner; Crystal W Burke; Mulu Z Tesfay; Pamela J Glass; William B Klimstra; Kate D Ryman
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

8.  A chimeric Sindbis-based vaccine protects cynomolgus macaques against a lethal aerosol challenge of eastern equine encephalitis virus.

Authors:  Chad J Roy; A Paige Adams; Eryu Wang; Grace Leal; Robert L Seymour; Satheesh K Sivasubramani; William Mega; Ilya Frolov; Peter J Didier; Scott C Weaver
Journal:  Vaccine       Date:  2013-01-16       Impact factor: 3.641

9.  Type I interferon induction is correlated with attenuation of a South American eastern equine encephalitis virus strain in mice.

Authors:  Christina L Gardner; Jun Yin; Crystal W Burke; William B Klimstra; Kate D Ryman
Journal:  Virology       Date:  2009-06-18       Impact factor: 3.616

10.  Eastern equine encephalitis in Latin America.

Authors:  Jean-Paul Carrera; Naomi Forrester; Eryu Wang; Amy Y Vittor; Andrew D Haddow; Sandra López-Vergès; Ivan Abadía; Elizabeth Castaño; Nestor Sosa; Carmen Báez; Dora Estripeaut; Yamilka Díaz; Davis Beltrán; Julio Cisneros; Hector G Cedeño; Amelia P Travassos da Rosa; Humberto Hernandez; Alex O Martínez-Torres; Robert B Tesh; Scott C Weaver
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.